Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

The IPO, which saw 25 million shares sold at $16, in the middle of the $15 to $17 range predicted by the company, continues a ...

US biotech Generate Biomedicines (Nasdaq: GENB) raised $400 million in its initial public offering, selling 25 million shares at $16 each, the midpoint of its range. It marks the largest biotech IPO ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

Promoted by Dr Krishna Ella, the vaccine manufacturer serves both domestic and export markets and remains entirely ...

Bharat Biotech is seeking to raise over $500 million through an IPO. Discussions are ongoing, and details may change. Established in 1996, the company has distributed over 9 billion vaccines worldwide ...

Indian vaccine developer Bharat Biotech International Ltd is considering an initial public offering that may raise more than ...

The developer of Covid-19 vaccine Covaxin, Bharat Biotech is considering an initial public offering that could raise over $500 million, according to sources cited by multiple reports.Discussions are ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. | Gilead penned a potential ...

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

While the first couple months of the year brought a steady stream of market entries from companies in sectors such as construction tech, space tech and biotech, new offerings from SaaS companies, long ...